The decision belongs with a licensed prescriber who weighs your goals, health, tolerability, and budget
Retatrutide has cleared a large hurdle in TRANSCEND-T2D-1, the first phase III trial testing the triple hormone receptor agonist in patients with type 2 diabetes, according to new top-line results released today by Lilly
Jump to: Quick comparison | How do Mounjaro and liraglutide work
Energy Balance Triple Receptor Activity Why Physician Supervision Matters Metabolic health and weight management are highly individual
Expected Insurance Coverage and Savings Programs When retatrutide commercially launches, the out-of-pocket cost for patients will depend heavily on insurance coverage and manufacturer assistance programs
Ghrelin displays strong growth hormone (GH)-releasing action mediated by the activation of the so-called GH secretagogue (GHS) receptor (GHS-R) type 1a